Breaking News Instant updates and real-time market news.

EBS

Emergent BioSolutions

$60.47

-0.4 (-0.66%)

16:36
10/15/18
10/15
16:36
10/15/18
16:36

Emergent BioSolutions completes Adapt Pharma acquisition

Emergent BioSolutions announced that it has completed its acquisition of Adapt Pharma and its flagship product NARCAN Nasal Spray, the first and only intranasal form of naloxone approved by the U.S. Food and Drug Administration and Health Canada, for the emergency treatment of known or suspected opioid overdose. With the closing of this transaction, Emergent also acquires a development pipeline of new treatment and delivery candidates to address opioid overdose and brings on approximately 50 employees, located in the U.S., Canada, and Ireland, including those responsible for supply chain management, research and development, government affairs, and commercial operations. Total consideration for the transaction is up to $735M, which includes an upfront payment of $635M and up to $100M in cash for potential sales-based milestones through 2022. At the closing, the company paid $635M, consisting of $60M in Emergent common stock and $575M in cash, subject to customary closing adjustments, using a combination of cash-on-hand and borrowings under its new $1.05B syndicated senior secured credit facilities that the company entered into to fund the transaction. The company will be issuing financial results in early November for the three and nine months ended September 30, at which time it will provide an update on the impact of this transaction on full-year 2018 guidance.

  • 01

    Nov

EBS Emergent BioSolutions
$60.47

-0.4 (-0.66%)

09/28/18
CANT
09/28/18
NO CHANGE
Target $42
CANT
Overweight
Opiant Pharmaceuticals price target raised to $42 from $32 at Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes raised his price target for Opiant Pharmaceuticals to $42 citing upwards earnings revisions for Narcan and a revised share count post the recently completed equity financing. The company is developing treatments focused on multiple addictions including a next-generation, improved Narcan, OPNT003, which has a longer half-life, offering better reversal outcomes in fentanyl-related overdoses, Folkes tells investors in a research note. He believes Emergent BioSolutions' recent acquisition of Adapt Pharma for $735M underscores the value of the opioid overdose market. As Opiant advances its pipeline, investors to begin to appreciate the market potential of its candidates, which should drive the stock higher, the analyst contends. Folkes reiterates an Overweight rating on the shares.
09/11/18
ARGS
09/11/18
NO CHANGE
Target $70
ARGS
Buy
Emergent BioSolutions price target raised to $70 from $62 at Argus
Argus analyst Jasper Hellweg raised his price target on Emergent BioSolutions to $70 and kept his Buy rating, saying the company's recent bullish stock trend has been driven by positive R&D and M&A developments. The analyst expects Emergent BioSolutions to produce "solid earnings growth over the next several years" thanks to the strong U.S. military demand for its BioThrax vaccine - the only FDA-approved vaccine for anthrax. Hellweg also cites the company's attractive valuation of 20-times his expected FY19 earnings, which is below the 26.3-times average multiple for its peer biotech group.
08/29/18
WELS
08/29/18
NO CHANGE
Target $65
WELS
Market Perform
Emergent deal for Adapt Pharma a 'bold' move with some risks, says Wells Fargo
Wells Fargo analyst David Maris said Emergent BioSolutions' agreement to acquire Adapt Pharma, the maker of Narcan nasal spray to treat opioid overdose, for about $735M is a "bold" move that some investors will like given the accretion and sales growth. However, some may see this as moving too far afield from its core business in biodefense and the deal may introduce overhang concerns about the duration of Narcan, added Maris. He raised his price target on Emergent shares to $65 from $61 and keeps a Market Perform rating on the stock.
08/29/18
CANT
08/29/18
NO CHANGE
Target $32
CANT
Overweight
Cantor sees value in Opiant after Emergent acquires Adapt Pharma
Cantor Fitzgerald analyst Brandon Folkes believes Emergent BioSolutions' (EBS) acquisition of Adapt Pharma underscores the potential for companies addressing the opioid overdose market. Opiant Pharmaceuticals (OPNT) is developing its own opioid overdose nasal spray, OPNT003, which could be of benefit in cases of synthetic opioid overdoses, such as with fentanyl, Folkes tells investors in a research note. He believes Opiant presents an attractive risk/reward at current share levels, "even if it captures only a portion of the growing market opioid overdose market." Folkes keeps an Overweight rating on the shares with a $32 price target.

TODAY'S FREE FLY STORIES

MSFT

Microsoft

$136.19

-0.2 (-0.15%)

15:07
10/23/19
10/23
15:07
10/23/19
15:07
On The Fly
Fly Intel: What to watch in Microsoft earnings report »

Microsoft (MSFT) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 14

    Nov

  • 21

    Nov

XOM

Exxon Mobil

$69.49

0.38 (0.55%)

15:06
10/23/19
10/23
15:06
10/23/19
15:06
Hot Stocks
Qilak LNG executes heads of agreement with ExxonMobil for natural gas »

Qilak LNG, a Lloyds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

XLNX

Xilinx

$93.83

-2.18 (-2.27%)

15:04
10/23/19
10/23
15:04
10/23/19
15:04
Options
Xilinx options imply 11.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 20

    Nov

FTNW

FTE Networks

$1.15

0.28 (32.18%)

14:52
10/23/19
10/23
14:52
10/23/19
14:52
Hot Stocks
Breaking Hot Stocks news story on FTE Networks »

FTE Networks Inc trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$254.68

-0.94 (-0.37%)

14:49
10/23/19
10/23
14:49
10/23/19
14:49
Options
Tesla options imply 11.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

KR

Kroger

$24.96

0.1 (0.40%)

14:45
10/23/19
10/23
14:45
10/23/19
14:45
Options
Kroger call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

14:45
10/23/19
10/23
14:45
10/23/19
14:45
General news
Treasury's $41 B 5-year auction was well supported »

Treasury's $41 B…

GSK

GlaxoSmithKline

$43.20

0.69 (1.62%)

, MYGN

Myriad Genetics

$32.14

-0.15 (-0.46%)

14:38
10/23/19
10/23
14:38
10/23/19
14:38
Hot Stocks
FDA approves niraparib for HRD-positive advanced ovarian cancer »

On October 23, the Food…

GSK

GlaxoSmithKline

$43.20

0.69 (1.62%)

MYGN

Myriad Genetics

$32.14

-0.15 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 30

    Oct

  • 06

    Nov

  • 13

    Nov

  • 07

    Dec

TSLA

Tesla

$253.92

-1.7 (-0.67%)

14:27
10/23/19
10/23
14:27
10/23/19
14:27
On The Fly
Fly Intel: What to watch in Tesla earnings report »

Tesla (TSLA) is scheduled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

14:25
10/23/19
10/23
14:25
10/23/19
14:25
Conference/Events
Senate Caucus on International Narcotics Control holds a hearing »

The Caucus holds a…

ALKS

Alkermes

$19.30

0.88 (4.78%)

14:22
10/23/19
10/23
14:22
10/23/19
14:22
Recommendations
Alkermes analyst commentary  »

Alkermes making some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

TSLA

Tesla

$253.68

-1.94 (-0.76%)

14:22
10/23/19
10/23
14:22
10/23/19
14:22
Periodicals
Tesla sued over Model S door handle malfunction, CCN says »

The family of a man who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FITB

Fifth Third

$28.11

-0.195 (-0.69%)

14:20
10/23/19
10/23
14:20
10/23/19
14:20
Options
Calls lead puts 8:1 in Fifth Third Bancorp as writer opens position »

Calls lead puts 8:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 29

    Oct

IBM

IBM

$134.05

0.02 (0.01%)

, GOOGL

Alphabet Class A

$1,252.30

11.22 (0.90%)

14:18
10/23/19
10/23
14:18
10/23/19
14:18
Periodicals
Google says computer achieves 'quantum supremacy,' Reuters reports »

Alphabet's Google…

IBM

IBM

$134.05

0.02 (0.01%)

GOOGL

Alphabet Class A

$1,252.30

11.22 (0.90%)

GOOG

Alphabet

$1,253.87

11.09 (0.89%)

MSFT

Microsoft

$136.15

-0.24 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 14

    Nov

  • 21

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/23/19
10/23
14:17
10/23/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/23/19
10/23
14:16
10/23/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$54.51

0.64 (1.19%)

, WBA

Walgreens Boots Alliance

$54.40

-0.93 (-1.68%)

14:12
10/23/19
10/23
14:12
10/23/19
14:12
On The Fly
Coca-Cola upgrade, Walgreens downgrade among today's top analyst calls »

Check out today's top…

KO

Coca-Cola

$54.51

0.64 (1.19%)

WBA

Walgreens Boots Alliance

$54.40

-0.93 (-1.68%)

SNAP

Snap

$13.23

-0.77 (-5.50%)

BIIB

Biogen

$277.71

-4.25 (-1.51%)

NOW

ServiceNow

$218.44

-9.82 (-4.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 28

    Oct

  • 21

    Nov

  • 09

    Dec

  • 12

    Dec

14:09
10/23/19
10/23
14:09
10/23/19
14:09
General news
5-Yr Note Auction Coupon Rate data reported »

5-Yr Note Auction Coupon…

14:09
10/23/19
10/23
14:09
10/23/19
14:09
General news
5-Yr Note Auction Total Amount data reported »

5-Yr Note Auction Total…

SWM

Schweitzer-Mauduit

$39.78

1.11 (2.87%)

14:07
10/23/19
10/23
14:07
10/23/19
14:07
Initiation
Schweitzer-Mauduit initiated  »

Schweitzer-Mauduit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARVN

Arvinas

$19.41

3.01 (18.35%)

14:07
10/23/19
10/23
14:07
10/23/19
14:07
Hot Stocks
Arvinas spikes 17% after platform update including Protac trial data »

Earlier today, Arvinas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

14:04
10/23/19
10/23
14:04
10/23/19
14:04
Periodicals
WeWork plans to cut up to 4,000 jobs in turnaround, FT reports »

WeWork (WE) plans to cut…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

CMCSA

Comcast

$45.65

-0.13 (-0.28%)

, CMCSK

Comcast

$0.00

(0.00%)

14:01
10/23/19
10/23
14:01
10/23/19
14:01
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CMCSA

Comcast

$45.65

-0.13 (-0.28%)

CMCSK

Comcast

$0.00

(0.00%)

DHR

Danaher

$137.96

0.76 (0.55%)

MMM

3M

$167.62

0.06 (0.04%)

NOC

Northrop Grumman

$349.80

-2.61 (-0.74%)

RTN

Raytheon

$202.20

-2.69 (-1.31%)

BAX

Baxter

$87.71

0.68 (0.78%)

DOW

Dow Inc.

$47.27

0.45 (0.96%)

HSY

Hershey

$149.87

0.14 (0.09%)

TWTR

Twitter

$38.30

-0.52 (-1.34%)

LUV

Southwest

$53.25

0.355 (0.67%)

TROW

T. Rowe Price

$109.40

1.4 (1.30%)

SWK

Stanley Black & Decker

$153.29

1.98 (1.31%)

HBAN

Huntington Bancshares

$14.48

0.045 (0.31%)

CTXS

Citrix

$103.72

-0.38 (-0.37%)

TSCO

Tractor Supply

$94.34

0.12 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 12

    Dec

HMC

Honda

$26.63

0.015 (0.06%)

14:00
10/23/19
10/23
14:00
10/23/19
14:00
Periodicals
Honda to sell only electric, hybrid cars in Europe starting in 2022, CNN says »

Honda said it intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EW

Edwards Lifesciences

$225.67

3.75 (1.69%)

, TSLA

Tesla

$255.10

-0.52 (-0.20%)

13:59
10/23/19
10/23
13:59
10/23/19
13:59
Earnings
Notable companies reporting after market close »

Notable companies…

EW

Edwards Lifesciences

$225.67

3.75 (1.69%)

TSLA

Tesla

$255.10

-0.52 (-0.20%)

PYPL

PayPal

$95.99

-1.41 (-1.45%)

MSFT

Microsoft

$136.25

-0.14 (-0.10%)

LVS

Las Vegas Sands

$59.16

0.58 (0.99%)

NOW

ServiceNow

$218.68

-9.58 (-4.20%)

F

Ford

$9.04

-0.025 (-0.28%)

LRCX

Lam Research

$233.15

-1.76 (-0.75%)

EBAY

eBay

$39.03

0.06 (0.15%)

ORLY

O'Reilly Automotive

$400.41

-0.16 (-0.04%)

XLNX

Xilinx

$95.26

-0.75 (-0.78%)

EFX

Equifax

$139.11

-0.15 (-0.11%)

ALGN

Align Technology

$217.63

4 (1.87%)

BMRN

BioMarin

$69.77

2.04 (3.01%)

FBHS

Fortune Brands

$58.73

0.22 (0.38%)

SLM

Sallie Mae

$9.10

0.04 (0.44%)

SAVE

Spirit Airlines

$37.74

0.49 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 13

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 07

    Dec

  • 09

    Dec

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.